Transcranial Magnetic Stimulation (TMS) Treatment for Alzheimer Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2011 by Hadassah Medical Organization.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT01334450
First received: April 12, 2011
Last updated: April 27, 2011
Last verified: April 2011
  Purpose

Transcranial Magnetic Stimulation (TMS) for treatment of Alzheimer disease.


Condition Intervention Phase
Alzheimer Disease
Device: TMS , H2-coil
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Treatment
Official Title: Deep-TMS for the Treatment of Alzheimer Disease Patients

Resource links provided by NLM:


Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • cognitive functioning score by ADAS-COG [ Time Frame: 4 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 42
Study Start Date: June 2011
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: High Frequency TMS to prefrontal cortex Device: TMS , H2-coil
Trans cranial magnetic stimulation with H2-coil
Other Name: Not relevant
Active Comparator: Low Frequency TMS to Prefrontal cortex Device: TMS , H2-coil
Trans cranial magnetic stimulation with H2-coil
Other Name: Not relevant
Sham Comparator: Sham TMS on Prefrontal Cortex Device: TMS , H2-coil
Trans cranial magnetic stimulation with H2-coil
Other Name: Not relevant

Detailed Description:

Transcranial Magnetic Stimulation (TMS) for treatment of Alzheimer disease.

Alzheimer's disease (AD) is the leading cause of dementia and cognitive deteriorating in the advanced age. The current medical treatment of AD is mainly symptomatic and has many limitation. This main target of this study is to determine the safety and efficacy of transcranial magnetic stimulation (TMS) using novel coil design (H2) for stimulation of deep brain structures concomitantly with regular treatment in Alzheimer's disease (AD) patients. TMS acts by generating magnetic fields in the brain which simulate neuro-chemical changes and stimulate neuronal activity translating into increased secretion of growth factors such as brain derived neurotrophic factor (BDNF). Hence it is postulated that TMS will have a positive effect on the cognitive and behavioral symptoms of patients with AD and may ameliorated the progression of the disease. The treatment is non-invasive, with no significant side effects, and no need of hospitalization or anesthesia. The trial is phase IIb double blind study including 45 AD patients ages between 50 to 80 with mild or moderate AD (Mini Mental State Examination [MMSE] between 16 to 26) divided into 3 groups. All participants will receive standard medical therapy for AD. In addition, patients recruited for the study will receive 16 sessions of TMS with the H2 coil over 8 weeks. The first group will receive excitatory stimulation of 10 Hz over the prefrontal and parietal cortex, the second group will receive inhibitory stimulation of 1 Hz over similar brain areas and control patients will receive the same amount of Sham sessions. Patient will receive 3 treatments per week in the first 3 weeks and than 1 treatment per week for additional 4 weeks. Patients will be evaluated before the treatments, after 8 weeks of treatment and after another 8 weeks without treatment. The evaluations will include cognitive function according to ADAS-COG and MMSE, Activity of daily living (ADL) functions according to ADSC-ADL, behavioral function according to the Neuropsychiatric Inventory (NPI), depression according to the Cornell Scale for Depression in Dementia (CSDD), care giver satisfaction according to the RUD LITE scale and computerized cognitive evaluation according to the NEXING battery. We expect that the cognitive, behavioral and ADL functions will improve better in the study group as compared to the Sham treated group. From previous trial of TMS in neurological patients, although not in AD, we anticipate that adverse events rate will be similar between groups proving the safety of deep TMS treatment in patients with AD. In case our hypothesis will be proven, deep TMS treatment will be added as an important modality to the conventional therapy of AD patients.

  Eligibility

Ages Eligible for Study:   50 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Men and women aged 50-85.
  2. Diagnosed with Alzheimer's disease for at least half a year (by the DSM-IV criteria).
  3. Scored between 16-26 on the MMSE.
  4. Received drug therapy for their disease, with each treatment having been administered at an acceptable dosage for at least 5 weeks.
  5. Existence of a routine therapist for changes or adverse effects reports.
  6. Existence of Alzheimer diagnosis by CT or MRI tests.
  7. Answered in the negative to all questions in the pre-TMS treatment safety questionnaire.
  8. Gave their oral and written consent to participate in the trial.

Exclusion Criteria:

  1. An additional neurological disorder.
  2. Severe psychiatric disorder.
  3. Uncontrolled hypertension, beyond 170/110.
  4. History of epilepsy, seizure, or heat convulsion or History of epilepsy or seizure in first degree relatives.
  5. History of head injury or stroke.
  6. History of metal implants in the head (except dental fillings)or History of surgery entailing metallic implants or known history of any metallic particles in the eye, implanted cardiac pacemaker, cochlear implants, use of neurostimulators, or any medical pumps.
  7. History of migraines in the last six months.
  8. History of drug or alcohol abuse.
  9. Inadequate communication with examiner.
  10. Participation in another clinical study, either concurrent with this trial or in the 3 months preceding it.
  11. Inability to sign a consent form.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01334450

Contacts
Contact: Ze'ev Meiner, Dr. 02-5844474 meiner@hadassah.org.il
Contact: Hamutal Shahar 02-5824030 hamutal@brainsway.com

Locations
Israel
Hadassah Medical Center Not yet recruiting
Jerusalem District, Israel, 91120
Contact: Orit Patkin       POrit@hadassah.org.il   
Principal Investigator: Ze'ev Meiner, Dr.         
Sponsors and Collaborators
Hadassah Medical Organization
Investigators
Principal Investigator: Zeev Meiner, Dr. Hadassah Medical Organization
  More Information

No publications provided

Responsible Party: Dr. Meiner Ze'ev, Hadassah Medical Center
ClinicalTrials.gov Identifier: NCT01334450     History of Changes
Other Study ID Numbers: 0316
Study First Received: April 12, 2011
Last Updated: April 27, 2011
Health Authority: Israel: Ministry of Health

Keywords provided by Hadassah Medical Organization:
Improvement of ADAS-COG

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Dementia
Mental Disorders
Nervous System Diseases
Neurodegenerative Diseases
Tauopathies

ClinicalTrials.gov processed this record on October 23, 2014